News
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...
Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference Plus: The biggest venture capitalists in healthcare on the Forbes Midas list By Katie Jennings , ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback